Rainer Metzger

Argobio SAS is a start-up studio founded in 2021 and based in Paris, FR. The company was initiated by Kurma Partners, a leading healthcare venture capital firm based in France, and Bpifrance, the French national investment bank. The French company aims to nurture and launch at least five breakthrough biotech companies over the next five years by sourcing innovative early-stage projects from renowned European academic research institutions. The focus is on selected therapeutic areas, including rare diseases, neurological disorders, oncology, and immunology. Argobio will identify, select, and incubate these projects up to company creation and beyond, providing broad expertise in the discovery and development of novel drugs with a team of highly experienced biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie, Poul Sørensen, and Rémi Soula. Thierry Laugel, Managing Partner at Partners, is the President of Argobio. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, an internationally renowned center for biomedical research.

Aurinvest Partenaires SAS is a private equity investment firm majority-owned by management. Aurinvest was established in 2001 and is located in Paris. The firm is organized as a partnership of business angels and operates as an investment club with approximately 60 members. The firm consists of a network of entrepreneurs holding stakes in a SCR risk capital investment company.

NBN Co. Ltd. designs, builds, and operates broadband network. It offers nbn Ethernet Bitstream service, a fiber, fixed wireless and satellite service; and fixed wireless network services. The firm operates fiber-to-the-premises, fiber-to-the-node, fiber-to-the-basement, hybrid fiber coaxial, fixed wireless, and satellite networks. The company was founded on April 9, 2009 and is headquartered in Sydney, Australia.

National Broadband Network provides an open-access data network project that includes both wired and radio communication components. The Australian company is ultimately controlled by the Government of Australia. William T. Morrow has been the CEO of the company since 2013.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands.

Eurazeo Investment Managr - EIM SA (Eurazeo IM) is a Venture Capital firm founded in 1997 by Christophe Bavière and part of the Eurazeo Group. Eurazeo Investment Manager - EIM SA is headquartered in Paris with additional offices in Frankfurt, Shanghai and Seoul. The firm is formerly known as Idinvest Partners SA, former AGF Private Equity SA.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.

Kurma Biofund seeks investment opportunities in life science and biotechnology companies located in Europe. The investments are done in cooperation with medical institutes and universities such as Institut Pasteur and Institut Curie. Its investment size ranges between €0.10 and €6 million.

Meiogenix SAS operates as a biotech company which develops breeding technologies. Its technology allows the modulation of the homologous recombination in eukaryotic cells. It facilitates the natural process that introduces genetic diversity in organisms allowing the generation of novel natural varieties. The company was founded by Giacomo Bastianelli and Alain Nicolas in 2011 and is headquartered in Paris, France.

Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain.

Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France.

DT Swiss Group AG provides components for bicycles. The company offers integrated production planning and control, online reporting in all business segments worldwide, comprehensive intercompany settlement and multi-plant processing services. DT Swiss Group is headquartered in Biel, Switzerland.